Progenics Pharmaceuticals Stock Price - PGNX

0.055 (1.4%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Progenics Pharmaceuticals Inc PGNX NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.055 1.4% 3.995 3.86 4.0201 4.00 3.94 12:14:04
Bid Price Ask Price Spread Spread % News
3.99 4.00 0.01 0.25% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,250 165,672 $ 3.95 $ 654,821 633,314 1.89 - 6.70
Last Trade Time Type Quantity Stock Price Currency
12:15:46 3 $ 4.00 USD

Progenics Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 345.95M 86.60M 84.68M $ 34.99M $ - -0.80 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Progenics Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PGNX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week3.754.12993.723.91531,4100.2456.53%
1 Month4.114.373.373.84603,622-0.115-2.8%
3 Months4.794.8351.893.49856,864-0.795-16.6%
6 Months5.346.701.894.25832,953-1.35-25.19%
1 Year4.566.701.894.74906,350-0.565-12.39%
3 Years6.579.41721.895.831,095,411-2.58-39.19%
5 Years5.379911.721.896.321,101,047-1.38-25.74%

Progenics Pharmaceuticals Description

Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.